cd19.car-ankt cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2019 (NCT03774654)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Hodgkin Disease · Phase 1
- Leukemia, B-Cell · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Lymphoid · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05487651 | Phase 1 | Oct 31, 2022 | Athenex, Inc., Baylor University |
| NCT03774654 | Phase 1 | Mar 31, 2019 | Baylor University, Methodist Cancer Center, Houston, Texas |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 2 | 1 | 1 | 2019 |
| Athenex, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1